Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia.
Wiesje Maria van der FlierMarjolein E de VugtEllen M A SmetsMarco BlomCharlotte E TeunissenPublished in: Nature aging (2023)
Alzheimer's disease (AD) is a major healthcare challenge with no curative treatment at present. To address this challenge, we need a paradigm shift, where we focus on pre-dementia stages of AD. In this Perspective, we outline a strategy to move towards a future with personalized medicine for AD by preparing for and investing in effective and patient-orchestrated diagnosis, prediction and prevention of the dementia stage. While focusing on AD, this Perspective also discusses studies that do not specify the cause of dementia. Future personalized prevention strategies encompass multiple components, including tailored combinations of disease-modifying interventions and lifestyle. By empowering the public and patients to be more actively engaged in the management of their health and disease and by developing improved strategies for diagnosis, prediction and prevention, we can pave the way for a future with personalized medicine, in which AD pathology is stopped to prevent or delay the onset of dementia.
Keyphrases
- mild cognitive impairment
- healthcare
- cognitive decline
- cognitive impairment
- current status
- end stage renal disease
- public health
- prognostic factors
- physical activity
- chronic kidney disease
- cardiovascular disease
- mental health
- ejection fraction
- emergency department
- rectal cancer
- metabolic syndrome
- type diabetes
- patient reported outcomes
- climate change
- health information
- patient reported